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INTRODUCTION 
Deflazacort (DFZ) is a glucocorticoid prescribed as an 
anti-inflammatory and immunosuppressant. It is a 
synthetic oxazoline derivative of prednisolone, having the 
molecular formula11beta, 21-dihydroxy-2′-methyl-5′beta-
H-pregna-1, 4-dieno [17,16d] oxazole-3, 20-dione-21-
acetate1.  DFZ administered orally is well-absorbed and 
converted by plasma esterases to pharmacologically active 
metabolite 21-desacetyl deflazacort (21-DFZ), which 
achieves peak plasma concentration in 1.5-2 hours. Its 
elimination plasma half-life is 1.1-1.9 hours. It is 40% 
protein-bound and has no affinity for corticosteroid 
binding globulin (transcortin). Elimination takes place 
primarily through the kidneys (70%). The remaining 30% 
is eliminated in the faeces2. 
Previously reported methods for determination of 21-DFZ 
include detection by high performance liquid 
chromatography3 and liquid chromatography-mass 
spectrometry (LC-MS) 4, 5, 6. The reported method based on 
LC-MS detection used the relatively tedious technique of 
liquid-liquid extraction (LLE) for analyte extraction from 
plasma 4, 5, 6. The other reported method used C18-
cartridge based solid phase extraction (SPE) extraction 
followed by semi-microbore liquid chromatography for 
determination of 21-DFZ using a high sample volume of 
2ml human plasma3 . The reported method lacks the 
selectivity and sensitivity offered by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) 
for high-throughput analysis of 21-DFZ. Quantification of 
drugs in biological matrices by LCMS is becoming more 
common due to the improved sensitivity and specificity of 
this technique7. SPE methods have better extraction 
efficiency, reproducibility and they yield cleaner extracts 
compared to LLE8.The polymer-based SPE cartridges 
provide greater analyte retention and overcome many 
limitations of the silica-based cartridges9. 
The primary objective was to develop and validate a rapid, 
sensitive and specific LC-MS/MS method for 21-DFZ 
estimation in human plasma. We applied this method to 
samples of a PK study of DFZ in 26 healthy volunteers 
after oral administration of 6 mg DFZ tablets of 
commercial product. 
EXPERIMENTAL 
Chemicals and Reagents  
21-DFZ (Figure 1) was procured from Toronto Research 
Chemicals Inc, Canada and Internal Standard (IS) 
prednisolone (Figure 1) was obtained from Sigma Aldrich, 
Germany. Acetonitrile (HPLC gradient grade), methanol 
(LCMS grade) and formic acid (puriss grade) were 
purchased from Sigma Aldrich, USA. Purified water was 
produced using Milli Q Gradient Millipore system 
(Millipore, USA). Drug free human plasma containing K3 
EDTA as anticoagulant was used as the blank matrix. 
 
 
Figure 1(A): Chemical Structures of  21-desacetyl 
deflazacort  
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Figure 1(B): Chemical Structures of IS (prednisolone). 
Instrumentation and chromatographic conditions 
Chromatographic separation was achieved by using Waters 
Acquity BEH C18 column having dimensions of 
50*2.1mm using a Waters Acquity UPLC system (Waters, 
USA). Formic acid (0.1%): Acetonitrile (20:80, v/v) was 
used as the mobile phase at a flow rate of 0.3 mL/min. The 
column temperature was set at 40°C and the sample 
compartment temperature was set at 5°C. 5µL of the 
sample was injected and the MS detection was performed 
using a Quattro Premier XE Mass spectrometer (Waters, 
USA) with an electrospray source. The desolvation 
temperature and source temperature were set at 400°C and 
110°C respectively. The electrospray source was operated 
in the positive ionization mode and m/z 400.06 → 123.91 
and 361.36 → 146.96 were monitored for quantitation of 
21-DFZ and prednisolone respectively. Data acquisition 
was performed with MassLynx software (Version 4.1, 
Waters, USA). 
Preparation of standards and Quality Control (QC) 
samples 
 Stock solutions of 21-DFZ and prednisolone were 
prepared in methanol (1mg/mL). Further dilutions of 21-
DFZ to make substocks were done using diluent (water: 
methanol 50:50) to obtain solutions of 0.0125 µg/mL, 
0.025 µg/mL, 0.150 µg/mL, 0.500 µg/mL, 1.000 µg/mL, 
1.60 µg/mL, 2.000 µg/mL and 2.50 µg/mL. Four levels of 
QCs (low, medium2 and high) were also prepared at 
concentrations of 0.0375µg/mL, 1.20µg/mL and 1.8 
µg/mL. 
The calibration curve standards were prepared by spiking 
the substocks in blank plasma to obtain concentration of 
0.50ng/mL, 1.00ng/mL, 6.0ng/mL, 20.0 ng/mL, 40.0 
ng/mL, 64.00 ng/mL, 80.00 ng/mL and 100.00 ng/mL 
respectively. 
The QC concentrations of 1.50 ng /mL, 48.0ng/mL and 
72.00ng/mL were prepared by spiking appropriate 21-DFZ 
QC substock solutions in blank human plasma. 
Sample preparation   
The plasma samples stored at -80°C were thawed at room 
temperature before processing. Ten microlitres of internal 
standard solution (prednisolone 5.0µg/mL) were added to 
250 µL of sample aliquoted in a centrifuge tube and mixed 
for 10 seconds. The sample was then loaded on the SPE 
cartridge previously conditioned with 1ml of methanol and 
equilibrated with 1ml of water. The cartridge was washed 
with 1ml of water and 0.5ml of 50%methanol in water. 
Elution was carried out using 0.5ml of 
methanol:acetonitrile(1:1). The elute was evaporated to 
dryness under a nitrogen stream at 40°C. The residue was 
dissolved in 150 µL of acetonitrile: water (80:20), 
transferred to a 96 well plate and injected into 
chromatographic system. 
Method Validation procedure 
The method was validated according to the recent US Food 
and Drug Administration (FDA) guidelines
10
. Specificity, 
linearity, lower limit of quantification (LLOQ), inter-day 
and intra-day precision and accuracy as well as recovery 
and stability of 21-DFZ were evaluated. The matrix effect 
and dilution integrity were also studied. 
Specificity 
The specificity of the method was determined by screening 
six different batches of blank human plasma. Blank and 
LLOQ level standards were prepared from each of the six 
lots as per the sample preparation method described 
earlier.  
Sensitivity 
Six samples at the LLOQ level were processed as per 
procedure and injected. The % CV and the % accuracy 
were calculated.  
Linearity/Calibration curve 
The calibration curves were constructed using values 
generated from the calibration standards by plotting the 
analyte to internal standard peak area ratios against 
concentration. The suitability of the curves was confirmed 
by back-calculating the concentrations of the calibration 
standards. 
Intra-day and intraday precision and accuracy (P&A) 
The intra-day precision and accuracy was performed by 
processing six samples at each QC level and analyzing 
against the calibration curve. The % CV and % accuracy at 
each QC level was calculated. For inter-day precision and 
accuracy, % CV and % accuracy of the QC samples at 
each of the five levels (LLOQ, LQC, MQC and HQC) of 
two consecutive P & A batches on different days were 
calculated.  
Recovery   
Aqueous solutions at the four QC levels were prepared. 
Recovery of analyte and internal standard from plasma 
was calculated by comparing the area response of analyte 
and drug in the extracted sample to the area response of the 
analyte and drug in the neat solution at the same 
concentrations.  
Matrix effect 
The matrix effect was evaluated by comparing the peak 
area ratios of analyte to IS in the post-extraction spiked 
blank plasma samples to the peak area ratios obtained by 
injecting neat standards directly. The matrix factor (MF) 
was calculated for all six samples at LQC and HQC levels 
and the matrix effect was determined by (MF-1) x100. 
 Reinjection reproducibility 
The QC samples at low QC and high QC levels of the 
precision and accuracy batch were reinjected after a gap of 
8 hours and analyzed against previously analysed 
calibration curve. The % change of the initially obtained 
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QC concentrations and those obtained after reinjection 
were calculated.  
Dilution integrity 
The effect of a 1:5 dilution on the determination of 21-
DFZ in human plasma was determined by measuring five 
samples of spiked DQC (dilution quality control) in human 
plasma. The DQC concentration (204.624 ng/mL) was two 
times the ULOQ concentration. The spiked samples were 
diluted 1:5 with drug free human plasma and then 
processed. The QC sample concentrations were calculated 
using appropriate dilution factor.  
Stability 
The stability of stock solutions of 21-DFZ and 
prednisolone were evaluated after storage for 36days at -
20°C. Stability of 21-DFZ in human plasma was assessed 
by analyzing 21-DFZ samples at two concentrations, low 
QC and high QC after exposing them to different 
conditions of time and temperature. The bench top stability 
was evaluated after exposure of the plasma samples at 
room temperature for 4.5 hours. The freeze thaw stability 
was determined after three freeze-thaw cycles from -80°C 
to room temperature at regular intervals. The samples were 
frozen at -80°C for 24 hours and thawed at room 
temperature. After complete thawing, the samples were 
refrozen at -80°C for 12-24 hrs at -80°C. This step was 
repeated two times. After the third thawing stage, the 
samples were analyzed. 
The long-term stability was assessed after storage of the 
test samples at -80°C and then analyzed after 42days of 
storage.  
The post-preparative storage stability of 21-DFZ was 
assessed by the autosampler stability and dried extract 
stability. The processed samples in vials were stored in the 
autosampler for 25 hours and then reinjected and analyzed 
against fresh calibration curve. 
For dried extract stability, the samples were processed till 
the evaporation step; the dried extracts were stored at -
80°C for 24 hrs. After 24 hrs, the frozen dried extracts 
were retrieved from the -80°C, thawed, reconstituted and 
analyzed against fresh calibration curve. 
Clinical Study 
The study protocol was approved by independent ethics 
committee and the study was conducted as per pertinent 
requirements of the current ICMR guidelines and USFDA 
adopted ICH guidelines for Good Clinical Practice and 
Declaration of Helsinki (Seoul 2008). An open label 
bioavailability investigation study in 26 healthy, adult, 
human subjects under fasting condition was conducted. 
One tablet of 6 mg DFZ were administered to the subjects 
along with 240ml of water and blood samples were 
collected at 0.50, 1.00, 1.25, 1.5, 1.75, 2.00, 2.25, 2.5, 
3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00, 20.00, 22.00, 
24.00, and 36.00 hrs. 
RESULTS AND DISCUSSION 
Method development:  MS and chromatographic 
development 
The MS tuning parameters and MS/MS fragmentation 
were optimized for both 21-DFZ and IS by varying the 
cone voltage and collision energy. Neat solutions of 
0.1µg/ml concentration were infused at a pump flow rate 
of 10µl/min in the ESI positive ion mode. The peak in the 
mass spectrum at m/z 400.06 corresponded to the 
protonated molecule (M+H) +of 21-DFZ. The most 
abundant daughter ion fragment at m/z 123.91 in the 
product ion spectrum was selected to obtain MRM 
transition to gain maximum sensitivity. Further, an MRM 
transition for prednisolone was also optimized under the 
same conditions. 
Full scan and product ion spectra of 21-desacetyl 
deflazacort and prednisolone are shown in Figure 2.
  
 
Figure 2(A): full scan spectra of 21-DFZ protonated molecule 
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Figure 2(B): product ion spectra of 21-DFZ  
 
Figure 2(C): full scan spectra of IS 
 
Figure 2(D): product ion spectra of IS. 
Prednisolone was chosen as a suitable internal standard as 
it is structurally related to 21-DFZ. Various compositions 
of acetonitrile and formic acid (0.1%) were investigated 
with a view to optimize the mobile phase for sensitivity, 
speed and peak shape. Acetonitrile and formic acid (0.1%) 
with a composition of 80:20 (v/v) gave better 
chromatographic results and was selected as the mobile 
phase. The retention time of both 21-DFZ and internal 
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standard was 0.45 min. Both polymer-based and 
monolithic LC columns were assessed for their suitability 
for the chromatographic separation of the analyte. A 
relatively short run time (2.0 min) was achieved with the 
short sub-2 micron column and a high organic content in 
the mobile phase. The typical chromatograms are shown in 
Figure 3. 
 
(A) 
 
(B) 
 
Figure 3: Representative chromatograms of (A) blank plasma sample and (B) plasma sample spiked with 21-
desacetyl deflazacort at lower limit of quantification (LLOQ). 
Method development:  Sample preparation  
Various sample preparation trials were carried out by LLE 
using several compositions of tertiary butyl methyl ether 
and diethyl ether: ethyl acetate. SPE methods were also 
evaluated with several modifications in washing & elution 
steps. SPE using polymer-sorbent cartridges gave 
reasonably good recovery without any blank interference. 
The SPE technique was chosen as the sample processing 
method over LLE for its consistent recovery, 
reproducibility and speed of analysis.  
Method Validation 
Selectivity 
All the six lots of tested plasma had no significant 
interfering peaks at the retention time of analyte or internal 
standards. All six lots met the acceptance criteria. 
Sensitivity 
The mean of the six samples prepared at the LLOQ 
concentration level was 95.3% with a CV of 4.0% 
Linearity 
The linear regression was fitted over the concentration 
range of 0.5 to 100 ng/mL of 21-DFZ in human plasma by 
a 1/x weighted least squares linear regression. For the four 
consecutive batches, the calibration curve standards 
showed an overall accuracy of 89.82 -107.90 % with RSD 
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of less than 14%. The results are shown in Table 1. Good 
linearity was obtained in the validated concentration range. 
The correlation coefficients of the 1/x weighted calibration 
curves from consecutive batches were in the range of 
0.997-0.999. A typical calibration curve is shown in Figure 
4.
 
Table 1: Precision and accuracy of calibration standards of 21-desacetyl deflazacort in human plasma from three 
consecutive validation batches 
Nominal calibration standard 
concentration (ng/ml) 
Mean Back-calculated calibration standard 
concentration (ng/ml) 
%CV  %Accuracy  
0.506 0.455 11.6 89.96 
1.011 0.980 14.0 96.97 
6.068 6.547 5.8 107.90 
20.227 21.572 0.4 106.65 
40.454 43.410 4.9 107.31 
64.727 58.138 3.6 89.82 
80.909 79.592 1.9 98.37 
101.136 104.344 1.4 103.17 
 
Figure 4: Representative Calibration Curve for the validated range of 0.5 to 100ng/ml 
Intra-day and inter-day precision and accuracy 
The resulting intra and inter-day precision and accuracy data for each spiked QC concentration are presented in Table 2.  
These results indicate that the method is reliable and reproducible within its analytical range. 
Table 2: Intraday and Interday Precision and accuracy of QC samples for 21-desacetyl deflazacort in human plasma 
QC levels Nominal QC 
concentration 
(ng/ml) 
Intraday Precision and accuracy (n=6) Interday Precision and accuracy (n=16) 
Mean 
(ng/ml) 
%CV %accuracy Mean 
(ng/ml) 
%CV %accuracy 
LLOQ 0.512 0.488 4.01 95.3 0.505 9.36 98.6 
LQC 1.535 1.364 6.76 88.9 1.424 10.85 92.8 
MQC 49.110 45.482 5.14 92.6 46.657 4.75 95.0 
HQC 73.665 70.441 6.73 95.6 72.904 7.22 99.0 
 
Recovery 
The recovery of 21-DFZ was 80.50%, 84.59% and 92.36% 
at the low QC, medium QC and high QC levels 
respectively. The mean global recovery of 21-DFZ across 
the three levels of QCs was 85.82±7.01%.  The results 
showed that 21-DFZ had consistent recovery across all 
four levels. The mean recovery of the internal standard 
was 76.94%. 
Matrix effect 
The mean matrix effect for both LQC and HQC 
concentrations was -3.35%. The result indicated that the 
samples were sufficiently cleaned up in the extraction 
procedure resulting in minimal matrix effect in the method.  
Re-injection reproducibility 
The mean % change in obtained QC concentrations after 
initial analysis and after reinjection was -1.56% at the 
LQC level, -5.48% at the MQC level and 7.02% at the 
 
Compound name: 21-DFZ  
Correlation coefficient: r = 0.999107, r^2 = 0.998215  
Calibration curve: 0.067114 * x + 0.00503812  
Curve type: Linear, Origin: Exclude, Weighting: 1/x 
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HQC level. The method met the acceptance criteria for 
reinjection reproducibility after 8 hrs. 
Dilution Integrity 
The six DQC samples processed after 1/5 dilution had an 
accuracy of 113.83% with a CV of 0.59%. The dilution 
integrity at 1/5 dilution met the acceptance criteria. 
Stability 
Acceptable stability was indicated in stock solution after 
storage at -20° C for 36 days for 21-DFZ and internal 
standard. Stability of 21-DFZ in plasma was demonstrated 
at bench top conditions for 4.5 hours and over three 
freeze/thaw cycles. 21-DFZ was found to be stable in 
plasma after long term storage at -80°C for 42days. The 
processed samples in the autosampler were stable for 25 
hrs at 5°C whereas the processed samples at the dry extract 
stage were stable at -80°C for 24 hrs. No significant 
degradation of 21-DFZ was observed in any of the stability 
test conditions and the results were consistent. The results 
are summarized in Table 3. 
 
Table 3: Summary of stability data of 21-desacetyl deflazacort in human plasma 
 
Clinical application 
The above validated LC-MS/MS method was successfully 
used to estimate pharmacokinetic parameters for 21-DFZ 
in human plasma. A mean plot of 21-DFZ concentration in 
plasma versus time was plotted from the data generated as 
shown in Figure 5.  The pharmacokinetic parameters were 
calculated using Winnonlin software (Version 5.3 
Pharsight, USA). The mean values were Cmax 38.19 
ng/ml, Tmax 1.00 hrs and AUC (0→t) 120.04 ng.hr/mL.
 
 
Figure 5: Mean Plasma concentration-time profile of 21-DFZ following administration of 1x6mg deflazacort 
formulation to healthy subjects in fasting condition (n=26). 
CONCLUSION 
A simple, rapid and sensitive LC-MS/MS method for the 
determination of 21-desacetyl Deflazacort in human 
plasma was developed. The method allows high sample 
through-put due to its short run time and relatively simple 
sample preparation procedure. This method is reliable, 
convenient and meets the criteria for application in clinical 
pharmacokinetic studies. 
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Stability condition Stability duration QC Level Mean Accuracy Mean Precision 
(%CV) 
Bench top 4.5hrs LQC 101.5 8.42 
HQC 93.2 11.83 
Freeze thaw 3cycles LQC 101.22 10.44 
HQC 99.40 7.04 
Long term 42 days LQC 107.28 12.61 
HQC 89.714 6.92 
Autosampler 25hrs LQC 102.8 4.28 
HQC 97.55 5.89 
Dried Extract 24hrs LQC 93.72 12.83 
HQC 95.70 9.15 
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